Norvell John Paul, Spivey James R
Division of Digestive Diseases, Department of Digestive Diseases, Department of Medicine, Emory Transplant Center, Emory University, 1365 Clifton Road, NE, Clinic B, Suite 1200, Atlanta, GA 30322, USA.
Division of Digestive Diseases, Department of Digestive Diseases, Department of Medicine, Emory Transplant Center, Emory University, 1365 Clifton Road, NE, Clinic B, Suite 1200, Atlanta, GA 30322, USA.
Clin Liver Dis. 2014 May;18(2):439-49. doi: 10.1016/j.cld.2014.01.005. Epub 2014 Feb 25.
Hepatic hydrothorax (HH) is an uncommon complication in patients with end-stage liver disease. Only 5% to 10% of patients with end-stage liver disease develop HH, which may result in dyspnea, hypoxia, and infection, and portends a poor prognosis. The most likely explanation for development is passage of fluid from the peritoneal space to the pleural space due to small diaphragmatic defects. Initial management consists of diuretics with dietary sodium restriction and thoracentesis, and a transjugular intrahepatic portosystemic shunt may ultimately be required. Afflicted patients can develop morbid and fatal complications, pose management dilemmas, and should warrant evaluation for liver transplantation.
肝性胸水(HH)是终末期肝病患者中一种罕见的并发症。终末期肝病患者中仅有5%至10%会发生HH,这可能导致呼吸困难、缺氧和感染,并预示预后不良。其发生的最可能原因是由于膈肌小缺损导致液体从腹腔间隙进入胸腔间隙。初始治疗包括使用利尿剂并限制饮食中的钠摄入以及胸腔穿刺抽液,最终可能需要行经颈静脉肝内门体分流术。患病患者可能会出现严重且致命的并发症,带来治疗难题,并且应该接受肝移植评估。